EPB 003
Alternative Names: EPB-003Latest Information Update: 01 Apr 2021
At a glance
- Originator Elpis Biopharmaceuticals
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Breast cancer; Non-small cell lung cancer
Most Recent Events
- 18 Mar 2021 EPB 003 is available for licensing as of 18 Mar 2021. https://elpisbiopharmaceuticals.com/partnering/ (Elpis Biopharmaceuticals pipeline, March 2021)
- 01 Mar 2021 Early research in Breast cancer in USA (Parenteral) (Elpis Biopharmaceuticals pipeline, March 2021)
- 01 Mar 2021 Early research in Non-small cell lung cancer in USA (Parenteral) (Elpis Biopharmaceuticals pipeline, March 2021)